Clinical trial
A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis
NCT00550862 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis
- Lead sponsor
- Intercept Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 31, 2007
- Completion date
- December 31, 2010
- Enrollment
- 165 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.